NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Artificial Intelligence is Propelling the Pharmaceutical Industry by Enabling Smart Drug Discovery Solutions Finds Frost & Sullivan - AI creates growth opportunities in novel therapeutics development by leveraging multi-sourced data, finds Frost & Sullivan - Frost.com
Artificial Intelligence is Propelling the Pharmaceutical Industry by Enabling Smart Drug Discovery Solutions Finds Frost & Sullivan

 

NewswireTODAY - /newswire/ - Santa Clara, CA, United States, 2018/12/17 - AI creates growth opportunities in novel therapeutics development by leveraging multi-sourced data, finds Frost & Sullivan - Frost.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Engineering / Artificial Intelligence Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

With 97 percent of all drug discovery programs failing, the development of a single new therapeutic involves an average cost of $2.6 billion. The complex industry/academia/government research framework involved in the discovery and development of new therapeutic products makes drug discovery an extremely laborious process. Consequently, more than 60 percent of known diseases remain untreatable. Life sciences companies, meanwhile, are making rapid strides in the fields of gene and cell therapies, omics technologies, and smart molecules approaches, creating an urgent need for advanced, cost- and time-effective technologies that can parse large databases of information to help develop novel therapies.

“Pharmaceutical companies are increasingly recognizing the value of deploying Artificial Intelligence (AI)-based platforms that can leverage data regarding gene mutations, protein targets, signaling pathways, disease events, and clinical trials to find hidden drug-disease correlations,” said Cecilia Van Cauwenberghe, Associate Fellow and TechVision Senior Industry Analyst at Frost & Sullivan. "This technology will enable scientists to derive structured and unstructured data from multiple sources as never before. Strategic collaborations with AI-driven companies can help large pharmaceutical companies establish a robust, AI-based pipeline as part of their portfolios and address new therapeutic areas."

Frost & Sullivan’s recent analysis, Artificial Intelligence Revolutionizing the Pharmaceutical Industry, presents the technology roadmap, trends, capabilities, and applications driven by AI in the pharmaceuticals industry. It includes stakeholders’ activities as well as industry initiatives and analyzes the investment environment, regional and global regulation landscape, and standardization approaches for tackling challenges.

AI-driven tools are encouraging companies to develop therapies for severely underserved areas and are also paving the way for precision medicine through a stratified therapeutics discovery and development approach. Collaborations among database holders, AI developers, and drug manufacturers will facilitate the early development of multiple therapeutics, even those focused on treating rare and chronic diseases.

AI-based technology companies are also empowered to make the most of scientific results and learning systems synergy to ensure a successful clinical translation of therapeutic, diagnostic, and theranostic developments. Some of the key applications of AI technologies in pharmaceuticals include:

• Drug development: Aids in disease modeling, drug design and development, lead identification, and drug repurposing.
• Candidates’ validation: Helps design and run pre-clinical trials, in silico/in vitro/in vivo studies, and investigational new drug (IND) process.
• Clinical trials: Supports all processes, from designing the trial to patient identification through data collection, analysis, and report generation.
• Regulatory approval: Facilitates the approval of application and process, labeling, and safety updates.
• Precision medicine: Accelerates the development of preventive and personalized care, treatment surveillance, and omics adaptive models.

"Overall, there is a profound and growing scientific understanding of many metabolic and signaling pathways, especially at molecular and genomic levels, which encourages the use of sophisticated technologies to develop groundbreaking therapies," noted Van Cauwenberghe. "As the underlying causes of many diseases remain vague and imprecise, AI-based approaches have emerged as the ideal mechanisms for finding novel treatments."

Artificial Intelligence Revolutionizing the Pharmaceutical Industry is part of Frost & Sullivan’s global Visionary Healthcare Growth Partnership Service program.

Frost & Sullivan's global TechVision practice is focused on innovation, disruption, and convergence and provides a variety of technology-based alerts, newsletters and research services as well as growth consulting services. Its premier offering, the TechVision program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt the innovation landscape, and drive transformational growth.

About Frost & Sullivan

For over five decades, Frost & Sullivan (frost.com) has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.

Artificial Intelligence Revolutionizing the Pharmaceutical Industry / D815-TV

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Engineering / Artificial Intelligence Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Engineering / Artificial Intelligence articles,
CATCH Visitors via Your Competitors Announcements!


Artificial Intelligence is Propelling the Pharmaceutical Industry by Enabling Smart Drug Discovery Solutions Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
AI-driven Tools | Frost & Sullivan
Contact: Mariana Fernandez - Frost.com 
210-348-10 12 / +54 11 4778 3540 mariana.fernandez[.]frost.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Engineering / Artificial Intelligence via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Engineering / Artificial Intelligence Most Recent Related Newswires:

Cornerstone and Meta Launch Strategic Partnership to Power the Future of AI, Extended Reality and Immersive Learning
Infineon Introduces DEEPCRAFT™ Brand for Edge AI Software Solutions and Launches New Ready Models
CentralSquare Launches CitizenLink AI™ to Reduce 911 Wait Times for Citizens by Automatically Handling Non-Emergency Calls
Oracle Named Category Leader in Inaugural Chartis Research AI Report
Bosch Service Solutions Recognized with Frost & Sullivan’s 2024 Technology Innovation Leadership Award for Revolutionizing the Intelligent Automation
GetFueled Emerges from Stealth with New Life Sciences-Focused Proposition and Rebranding
AIMed24 Announces Strategic Partnership with Frost & Sullivan
OpenText Report Raises Awareness for Consumer Digital Life Protection as Privacy Concerns Increase with Generative AI Use
Oracle Announces New AI Features in Argus - Automate Translations to Speed Safety Case Processing
Infor Targets Business Velocity with Added Process Mining, ESG and GenAI Capabilities
Alstom and Flox Receive SEK 3.3 Million from Vinnova to Test AI Technology to Combat Railway Wildlife Accidents
OM1 Earns Product Innovation Award for Transforming Real-world Evidence Analytics Solutions Industry with its Pioneering AI-powered Platforms
Duke Health and SAS Formalize Strategic Analytics and AI Collaboration
ZF and Infineon Use AI Algorithms to Optimize Software and Control Units for Driving Dynamics
Oracle Introduces an AI-centric Generative Development Infrastructure for Enterprises

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  JobsWare.com

Visit  Limelon Advertising, Co.





 
  ©2005-2024 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)